From Yahoo Finance: 2025-06-11 20:01:00

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been identified as one of the 13 Biotech Stocks with Huge Upside Potential, with JPMorgan maintaining an Overweight rating despite reducing its price target from $950 to $800.

The recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares following poor IL-33 data in late May is deemed “very much overdone” by the company.

JPMorgan remains optimistic about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), emphasizing assets like Dupixent and Eylea that support financial stability, projecting significant upside potential with an updated $800 price target.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) focuses on developing drugs for eye disease, cardiovascular disease, cancer, and inflammation, positioning it as a stock with significant upside potential in the biotech sector.

While Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shows promise as an investment, other AI stocks may offer greater upside potential with less downside risk according to analysts. No promotional content was included in the news article.



Read more at Yahoo Finance: JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target